Medical Aspects of the Persistent Vegetative State
NEJM 330:1499-1508, 1572-15791994., Annas,G.J.,et al, 1994
Clinical Characteristics of Patients in the Persistent Vegetative State
Arch Int Med 151:930-932, 855-8561991., Tresch,D.D.,et al, 1991
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Genetic Aspects of Alzheimer Disease
The Neurologist 15:80-86, Williamson,J.,et al, 2009
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Genetic Testing for Alzheimer Disease, Practical and Ethical Issues
Arch Neurol 54:1226-1229, Roses,A.D., 1997
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Genetic Factors in Alzheimer's Disease:A Review of Recent Advances
Ann Neurol 40:829-840, Levy-Lahad,E.&Bird,T.D., 1996
Apolipoprotein E Allele E4, Dementia, and Cognitive Decline in a Population Sample
Lancet 346:1387-1390, Henderson,A.S.,et al, 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
Apoliprprotein E E4 Allele & the Lifetime Risk of Alzheimer's Disease:What Physicians Know, & What They Should Know
Arch Neurol 52:1074-1079, Seshadri,S.,et al, 1995
Apolipoprotein E Genotype in Patients with Alzheimer's Disease:Implications for Risk of Dementia Among Relatives
Ann Neurol 38:797-808, Farrer,L.A.,et al, 1995
Posterior Cortical Atrophy:Neuropathologic Correlations
Arch Neurol 51:269-274, Victoroff,J.,et al, 1994
Brain Single-Photon Emission Computed Tomography
Neurol 44:1970-1977, Masdeu,J.C.,et al, 1994
The Older Driver, Clinical Assessment and Injury Prevention
Arch Int Med 152:735-740, Underwood,M., 1992
Assessment of Competency:The Role of Neurobehavioral Deficits
Ann Int Med 115:203-208, Freedman,M.,et al, 1991
BA4 Amyloid Protein Deposition in Brain After Head Trauma
Lancet 338:1422-1423, Roberts,G.W.,et al, 1991
Clinical Genetics and Genetic Counseling in Alzheimer Disease
Ann Int Med 115:601-606, Breitner,J.C.S., 1991
Immunocytochemistry of Neurofibrillary Tangles in Dementia Pugilistica and Alzheimer's Disease:Evidence for Common Genesis
Lancet 2:1456-1458, Roberts,G.W., 1988
The Human Kluver-Bucy Syndrome
Neurol 33:1141-1145, Lilly,R.,et al, 1983
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Posttraumatic Premature Alzheimer's Disease
Arch Neurol 39:570-575, Rudelli,R.,et al, 1982
Normal Pressure Hydrocephalus
In Wells C. E. Dementia 2nd Ed, F. A. Davis Co, Phila, P. 69-92, Katzman,R., 1977
Progressive Dementia-"Aspects of Diagnosis"
Hospital Physician, Nov 1970, p. 84., , 1970
Neuropathologic Changes in People with Essential Tremor With Dementia
Neurol 105:e214310, Wainman,E.,et al, 2025
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Debate Sparks Over LATE, a Recently Recognized Dementia
JAMA 322:914-916, Abbasi, J., 2019
Outcomes after Diagnosis of Mild Cognitive Impairment in a Large Autopsy Series
Ann Neurol 81:549-559, Abner, E.L.,et al, 2017
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
CSF biomarkers in posterior cortical atrophy
Neurol 76:1782-1788, Seguin, J.et al, 2011
Rapidly Progressive Alzheimer Disease
Arch Neurol 68:1124-1130, Schmidt, C.,et al, 2011
Rapidly Progressive Neurodegenerative Dementias
Arch Neurol 66:201-207, Josephs,K.A.,et al, 2009
Age, Neuropathology, and Dementia
NEJM 360:2302-2309, Savva,G.M.,et al, 2009
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Joint Effect of Stroke and APOE 4 on Dementia Risk: The Canadian Study of Health and Aging
Neurol 70:9-16,5, Jin,Y.P.,et al, 2008
Long-Term Effects of A�42 Immunisation in Alzheimers Disease: Follow-Up of a Randomised, Placebo-Controlled Phase I Trial
Lancet 372:216-223,180, Holmes,C.,et al., 2008
Superficial Siderosis: A Potential Diagnostic Marker of Cerebral Amyloid Angiopathy in Alzheimer Disease
Stroke 39:2894-2897,2699, Feldman,H.H.,et al, 2008
Neuropathologic Features of Amnestic Mild Cognitive Impairment
Arch Neurol 63:665-672,645, Petersen,R.C.,et al, 2006
Frontotemporal Dementia: Clinicopathological Correlations
Ann Neurol 59:952-962, Forman,M.S.,et al, 2006
A-beta Vaccination Effects on Plaque Pathology in the Absence of Encephalitis in Alzheimer Disease
Neurol 64:129-131,10, Masliah,E.,et al, 2005
Progressive Posterior Cortical Dysfunction
Neurol 63:1175-1180, Renner,J.A.,et al, 2004
Clinical, Genetic, and Neuropathologic Characteristics of Posterior Cortical Atrophy
Neurol 63:1168-1174, Tang-Wai,D.F.,et al, 2004